JP2019516719A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019516719A5 JP2019516719A5 JP2018560595A JP2018560595A JP2019516719A5 JP 2019516719 A5 JP2019516719 A5 JP 2019516719A5 JP 2018560595 A JP2018560595 A JP 2018560595A JP 2018560595 A JP2018560595 A JP 2018560595A JP 2019516719 A5 JP2019516719 A5 JP 2019516719A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- group
- guanosine
- mrna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 6
- 150000002632 lipids Chemical class 0.000 claims 6
- 108020004999 messenger RNA Proteins 0.000 claims 6
- 102000005840 alpha-Galactosidase Human genes 0.000 claims 4
- 108010030291 alpha-Galactosidase Proteins 0.000 claims 4
- 229940124447 delivery agent Drugs 0.000 claims 4
- 239000002105 nanoparticle Substances 0.000 claims 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 4
- 108700026244 Open Reading Frames Proteins 0.000 claims 3
- 229940029575 guanosine Drugs 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 108020005345 3' Untranslated Regions Proteins 0.000 claims 2
- 108020003589 5' Untranslated Regions Proteins 0.000 claims 2
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims 2
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims 2
- 208000024720 Fabry Disease Diseases 0.000 claims 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Natural products C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 1
- HWPZZUQOWRWFDB-UHFFFAOYSA-N 1-methylcytosine Chemical compound CN1C=CC(N)=NC1=O HWPZZUQOWRWFDB-UHFFFAOYSA-N 0.000 claims 1
- RGICCULPCWNRAB-UHFFFAOYSA-N 2-[2-(2-hexoxyethoxy)ethoxy]ethanol Chemical compound CCCCCCOCCOCCOCCO RGICCULPCWNRAB-UHFFFAOYSA-N 0.000 claims 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 1
- JRYMOPZHXMVHTA-DAGMQNCNSA-N 2-amino-7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JRYMOPZHXMVHTA-DAGMQNCNSA-N 0.000 claims 1
- BGTXMQUSDNMLDW-AEHJODJJSA-N 2-amino-9-[(2r,3s,4r,5r)-3-fluoro-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@]1(O)F BGTXMQUSDNMLDW-AEHJODJJSA-N 0.000 claims 1
- KELXHQACBIUYSE-UHFFFAOYSA-N 5-methoxy-1h-pyrimidine-2,4-dione Chemical compound COC1=CNC(=O)NC1=O KELXHQACBIUYSE-UHFFFAOYSA-N 0.000 claims 1
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 claims 1
- 241000180579 Arca Species 0.000 claims 1
- 101150077194 CAP1 gene Proteins 0.000 claims 1
- 101150014715 CAP2 gene Proteins 0.000 claims 1
- 229930010555 Inosine Natural products 0.000 claims 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims 1
- 101100245221 Mus musculus Prss8 gene Proteins 0.000 claims 1
- 101100260872 Mus musculus Tmprss4 gene Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 229960003786 inosine Drugs 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 235000000346 sugar Nutrition 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- ZEMGGZBWXRYJHK-UHFFFAOYSA-N thiouracil Chemical compound O=C1C=CNC(=S)N1 ZEMGGZBWXRYJHK-UHFFFAOYSA-N 0.000 claims 1
- 229950000329 thiouracil Drugs 0.000 claims 1
- 229940113082 thymine Drugs 0.000 claims 1
- 229940035893 uracil Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022119527A JP2022136230A (ja) | 2016-05-18 | 2022-07-27 | ファブリー病の治療のためのα－ガラクトシダーゼＡをコードするポリヌクレオチド |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662338354P | 2016-05-18 | 2016-05-18 | |
| US62/338,354 | 2016-05-18 | ||
| PCT/US2017/033398 WO2017201328A1 (en) | 2016-05-18 | 2017-05-18 | POLYNUCLEOTIDES ENCODING α-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022119527A Division JP2022136230A (ja) | 2016-05-18 | 2022-07-27 | ファブリー病の治療のためのα－ガラクトシダーゼＡをコードするポリヌクレオチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019516719A JP2019516719A (ja) | 2019-06-20 |
| JP2019516719A5 true JP2019516719A5 (enExample) | 2020-06-25 |
| JP7114485B2 JP7114485B2 (ja) | 2022-08-08 |
Family
ID=59021568
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018560595A Active JP7114485B2 (ja) | 2016-05-18 | 2017-05-18 | ファブリー病の治療のためのα－ガラクトシダーゼＡをコードするポリヌクレオチド |
| JP2022119527A Pending JP2022136230A (ja) | 2016-05-18 | 2022-07-27 | ファブリー病の治療のためのα－ガラクトシダーゼＡをコードするポリヌクレオチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022119527A Pending JP2022136230A (ja) | 2016-05-18 | 2022-07-27 | ファブリー病の治療のためのα－ガラクトシダーゼＡをコードするポリヌクレオチド |
Country Status (6)
| Country | Link |
|---|---|
| US (5) | US10494636B2 (enExample) |
| EP (2) | EP3896164A1 (enExample) |
| JP (2) | JP7114485B2 (enExample) |
| AU (1) | AU2017266932B2 (enExample) |
| CA (1) | CA3024507A1 (enExample) |
| WO (1) | WO2017201328A1 (enExample) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9725710B2 (en) | 2014-01-08 | 2017-08-08 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| SG10201912038TA (en) | 2014-04-23 | 2020-02-27 | Modernatx Inc | Nucleic acid vaccines |
| US20170360900A1 (en) | 2014-12-22 | 2017-12-21 | Codexis, Inc. | Human alpha-galactosidase variants |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| MA42502A (fr) | 2015-07-21 | 2018-05-30 | Modernatx Inc | Vaccins contre une maladie infectieuse |
| WO2017020026A1 (en) | 2015-07-30 | 2017-02-02 | Modernatx, Inc. | Concatemeric peptide epitopes rnas |
| WO2017031232A1 (en) | 2015-08-17 | 2017-02-23 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| CA2998810A1 (en) | 2015-09-17 | 2017-03-23 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| EP4349405A3 (en) | 2015-10-22 | 2024-06-19 | ModernaTX, Inc. | Respiratory virus vaccines |
| EA201891001A1 (ru) | 2015-10-22 | 2018-11-30 | МОДЕРНАТиЭкс, ИНК. | Вакцины на основе нуклеиновых кислот против вируса ветряной оспы (vzv) |
| EP3364950A4 (en) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | VACCINES AGAINST TROPICAL DISEASES |
| WO2017070613A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| ES2924407T3 (es) * | 2015-12-10 | 2022-10-06 | Modernatx Inc | Composiciones y procedimientos para el suministro de agentes terapéuticos |
| SMT202200252T1 (it) | 2015-12-22 | 2022-07-21 | Modernatx Inc | Composti e composizioni per il rilascio intracellulare di agenti |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| EP3896164A1 (en) | 2016-05-18 | 2021-10-20 | ModernaTX, Inc. | Polynucleotides encoding alpha-galactosidase a for the treatment of fabry disease |
| EP3458107B1 (en) | 2016-05-18 | 2024-03-13 | ModernaTX, Inc. | Polynucleotides encoding jagged1 for the treatment of alagille syndrome |
| CN109937253B (zh) | 2016-09-14 | 2023-06-30 | 摩登纳特斯有限公司 | 高纯度rna组合物及其制备方法 |
| MA46584A (fr) | 2016-10-21 | 2019-08-28 | Modernatx Inc | Vaccin contre le cytomégalovirus humain |
| EP3538146A4 (en) | 2016-11-11 | 2020-07-15 | ModernaTX, Inc. | INFLUENZA VACCINE |
| MA50335A (fr) | 2016-12-08 | 2020-08-19 | Modernatx Inc | Vaccins à acide nucléique contre des virus respiratoires |
| US11384352B2 (en) | 2016-12-13 | 2022-07-12 | Modernatx, Inc. | RNA affinity purification |
| EP3596041B1 (en) | 2017-03-15 | 2022-11-02 | ModernaTX, Inc. | Compound and compositions for intracellular delivery of therapeutic agents |
| US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
| WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
| EP3595713A4 (en) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | Respiratory syncytial virus vaccine |
| US11576961B2 (en) | 2017-03-15 | 2023-02-14 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| AU2018234828A1 (en) | 2017-03-15 | 2019-09-19 | Modernatx, Inc. | Lipid nanoparticle formulation |
| AU2018234814B2 (en) | 2017-03-15 | 2022-06-30 | Modernatx, Inc. | Crystal forms of amino lipids |
| EP3595676A4 (en) | 2017-03-17 | 2021-05-05 | Modernatx, Inc. | RNA VACCINES AGAINST ZOONOSES |
| CA3056812C (en) * | 2017-03-23 | 2022-11-29 | Medicago Inc. | Norovirus fusion proteins and vlps comprising norovirus fusion proteins |
| WO2018172556A1 (en) | 2017-03-24 | 2018-09-27 | Curevac Ag | Nucleic acids encoding crispr-associated proteins and uses thereof |
| EP3607074A4 (en) | 2017-04-05 | 2021-07-07 | Modernatx, Inc. | REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY |
| WO2018232120A1 (en) | 2017-06-14 | 2018-12-20 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| WO2018232357A1 (en) | 2017-06-15 | 2018-12-20 | Modernatx, Inc. | Rna formulations |
| EP3668979A4 (en) | 2017-08-18 | 2021-06-02 | Modernatx, Inc. | METHOD OF HPLC ANALYSIS |
| EP4397757A3 (en) | 2017-08-18 | 2024-10-23 | ModernaTX, Inc. | Rna polymerase variants |
| EP3668977A4 (en) | 2017-08-18 | 2021-04-21 | Modernatx, Inc. | HPLC ANALYTICAL PROCESSES |
| US11744801B2 (en) | 2017-08-31 | 2023-09-05 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| EP3681514A4 (en) | 2017-09-14 | 2021-07-14 | ModernaTX, Inc. | RNA VACZINE AGAINST ZIKA VIRUS |
| US10785574B2 (en) | 2017-12-14 | 2020-09-22 | Flodesign Sonics, Inc. | Acoustic transducer driver and controller |
| CN111712468A (zh) | 2017-12-22 | 2020-09-25 | 北卡罗莱纳州立大学 | 聚合物荧光团、包含其的组合物及制备和使用其的方法 |
| MA54676A (fr) | 2018-01-29 | 2021-11-17 | Modernatx Inc | Vaccins à base d'arn contre le vrs |
| EP3746052A1 (en) * | 2018-01-30 | 2020-12-09 | Modernatx, Inc. | Compositions and methods for delivery of agents to immune cells |
| US12162994B2 (en) | 2018-03-02 | 2024-12-10 | Sigilon Therapeutics, Inc. | Biocompatible hydrogel capsules and process for preparing same |
| UY38160A (es) | 2018-04-04 | 2019-11-29 | Sigilon Therapeutics Inc | Partículas implantables y métodos relacionados |
| WO2020061367A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| WO2020061284A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Peg lipids and uses thereof |
| JP7640452B2 (ja) | 2018-09-19 | 2025-03-05 | モデルナティエックス インコーポレイテッド | 高純度ｐｅｇ脂質及びそれらの使用 |
| WO2020061457A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| US11427813B2 (en) | 2018-12-20 | 2022-08-30 | Codexis, Inc. | Human alpha-galactosidase variants |
| WO2020142752A1 (en) * | 2019-01-04 | 2020-07-09 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of fabry disease |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
| MA55037A (fr) | 2019-02-20 | 2021-12-29 | Modernatx Inc | Variants d'arn polymérase pour le coiffage co-transcriptionnel |
| MX2021011031A (es) | 2019-03-11 | 2021-12-10 | Modernatx Inc | Proceso de transcripción in vitro en lotes alimentados. |
| US12070495B2 (en) | 2019-03-15 | 2024-08-27 | Modernatx, Inc. | HIV RNA vaccines |
| WO2020198685A1 (en) * | 2019-03-27 | 2020-10-01 | Sigilon Therapeutics, Inc. | Compositions, devices and methods for treating fabry disease |
| EP3965830A1 (en) * | 2019-05-07 | 2022-03-16 | ModernaTX, Inc. | Differentially expressed immune cell micrornas for regulation of protein expression |
| JP7766583B2 (ja) * | 2019-08-07 | 2025-11-10 | モデルナティエックス インコーポレイテッド | 強化された薬剤送達のための組成物及び方法 |
| US11066355B2 (en) | 2019-09-19 | 2021-07-20 | Modernatx, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
| JP2023516301A (ja) * | 2020-02-28 | 2023-04-19 | コデクシス， インコーポレイテッド | ヒトアルファ－ガラクトシダーゼ変異体 |
| WO2021183895A1 (en) * | 2020-03-13 | 2021-09-16 | Biomarin Pharmaceutical Inc. | Treatment of fabry disease with aav gene therapy vectors |
| CN113874507A (zh) | 2020-04-09 | 2021-12-31 | 苏州艾博生物科技有限公司 | 冠状病毒的核酸疫苗 |
| IL297084A (en) | 2020-04-09 | 2022-12-01 | Suzhou Abogen Biosciences Co Ltd | Lipid nanoparticle compounds |
| KR102314642B1 (ko) * | 2020-04-17 | 2021-10-20 | 재단법인 아산사회복지재단 | 파브리 병 진단용 바이오 마커 및 이의 용도 |
| WO2021213924A1 (en) | 2020-04-22 | 2021-10-28 | BioNTech SE | Coronavirus vaccine |
| CA3175905A1 (en) * | 2020-04-27 | 2021-11-04 | David H. Kirn | Codon optimized gla genes and uses thereof |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| AU2021360494A1 (en) | 2020-10-14 | 2023-05-18 | George Mason Research Foundation, Inc. | Ionizable lipids and methods of manufacture and use thereof |
| US12329811B2 (en) | 2021-01-11 | 2025-06-17 | Modernatx, Inc. | Seasonal RNA influenza virus vaccines |
| US20240301380A1 (en) * | 2021-01-14 | 2024-09-12 | Spark Therapeutics, Inc. | Compositions and Methods for Treating Fabry Disease |
| NL2027654B1 (en) * | 2021-02-08 | 2022-09-09 | Nutcracker Therapeutics Inc | Methods for manufacturing a syntetic template |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| US20230340077A1 (en) * | 2021-12-01 | 2023-10-26 | Luyef Biotechnologies Inc. | Production of myoglobin from trichoderma using a feeding media |
| KR20240148846A (ko) * | 2022-01-20 | 2024-10-11 | 오하이오 스테이트 이노베이션 파운데이션 | 지질 화합물을 포함하는 조성물과 이의 제조 및 사용 방법 |
| CN114672501B (zh) * | 2022-05-27 | 2022-08-23 | 珠海丽凡达生物技术有限公司 | 一种mRNA、药物组合物及其应用 |
| US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5082767A (en) | 1989-02-27 | 1992-01-21 | Hatfield G Wesley | Codon pair utilization |
| US20090017533A1 (en) | 1998-09-29 | 2009-01-15 | Shire Human Genetic Therapies, Inc., A Delaware Corporation | Optimized messenger rna |
| AU6270499A (en) | 1998-09-29 | 2000-04-17 | Phylos, Inc. | Synthesis of codon randomized nucleic acids |
| AR034853A1 (es) | 2000-10-11 | 2004-03-24 | Transkaryotic Therapies Inc | Secuencia de acido nucleico sintetico que codifica una alfa-galactosidasa, vector y celula que la comprenden, metodo para producir alfa-galactosidasa, metodo para prepararla, composicion farmaceutica que comprende dicha secuencia y su uso para preparar esta ultima |
| PT1857122E (pt) | 2001-06-05 | 2011-03-07 | Curevac Gmbh | Arnm estabilizado com teor de g/c aumentado, codificando para um antigénio viral |
| IL161100A0 (en) | 2001-09-28 | 2004-08-31 | Max Planck Gesellschaft | Identification of novel genes coding for small temporal rnas |
| US20040005600A1 (en) | 2002-04-01 | 2004-01-08 | Evelina Angov | Method of designing synthetic nucleic acid sequences for optimal protein expression in a host cell |
| DE10260805A1 (de) | 2002-12-23 | 2004-07-22 | Geneart Gmbh | Verfahren und Vorrichtung zum Optimieren einer Nucleotidsequenz zur Expression eines Proteins |
| EP1648914A4 (en) | 2003-07-31 | 2009-12-16 | Regulus Therapeutics Inc | OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA |
| US8101385B2 (en) | 2005-06-30 | 2012-01-24 | Archemix Corp. | Materials and methods for the generation of transcripts comprising modified nucleotides |
| US8105813B2 (en) | 2005-06-30 | 2012-01-31 | Archemix Corp. | Materials and methods for the generation of fully 2′-modified nucleic acid transcripts |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| US20080046192A1 (en) | 2006-08-16 | 2008-02-21 | Richard Lathrop | Polypepetide-encoding nucleotide sequences with refined translational kinetics and methods of making same |
| EP2207891B1 (en) | 2006-12-22 | 2012-07-25 | Archemix LLC | Materials and methods for the generation of transcripts comprising modified nucleotides |
| WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| BRPI0817231B1 (pt) | 2007-09-26 | 2020-06-09 | Intrexon Corp | vetor de expressão, método para expressar uma sequência de interesse em uma célula hospedeira e kit compreendendo o dito vetor |
| WO2009075886A1 (en) | 2007-12-11 | 2009-06-18 | The Scripps Research Institute | Compositions and methods related to mrna translational enhancer elements |
| US7561973B1 (en) | 2008-07-31 | 2009-07-14 | Dna Twopointo, Inc. | Methods for determining properties that affect an expression property value of polynucleotides in an expression system |
| US8401798B2 (en) | 2008-06-06 | 2013-03-19 | Dna Twopointo, Inc. | Systems and methods for constructing frequency lookup tables for expression systems |
| US8126653B2 (en) | 2008-07-31 | 2012-02-28 | Dna Twopointo, Inc. | Synthetic nucleic acids for expression of encoded proteins |
| PL215513B1 (pl) | 2008-06-06 | 2013-12-31 | Univ Warszawski | Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka |
| KR102066189B1 (ko) | 2009-06-10 | 2020-01-14 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| US20110082055A1 (en) | 2009-09-18 | 2011-04-07 | Codexis, Inc. | Reduced codon mutagenesis |
| WO2012075040A2 (en) | 2010-11-30 | 2012-06-07 | Shire Human Genetic Therapies, Inc. | mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES |
| US9999673B2 (en) | 2011-01-11 | 2018-06-19 | Alnylam Pharmaceuticals, Inc. | PEGylated lipids and their use for drug delivery |
| DE12722942T1 (de) * | 2011-03-31 | 2021-09-30 | Modernatx, Inc. | Freisetzung und formulierung von manipulierten nukleinsäuren |
| ES2987057T3 (es) | 2011-06-08 | 2024-11-13 | Translate Bio Inc | Lípidos escindibles |
| JP6184945B2 (ja) | 2011-06-08 | 2017-08-23 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | ｍＲＮＡ送達のための脂質ナノ粒子組成物および方法 |
| WO2013016058A1 (en) | 2011-07-22 | 2013-01-31 | Merck Sharp & Dohme Corp. | Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery |
| EP2755986A4 (en) | 2011-09-12 | 2015-05-20 | Moderna Therapeutics Inc | MANIPULATED NUCLEIC ACIDS AND METHOD OF APPLICATION THEREFOR |
| HRP20220250T1 (hr) | 2011-10-03 | 2022-04-29 | Modernatx, Inc. | Modificirani nukleozidi, nukleotidi i nukleinske kiseline, te njihove uporabe |
| SG10201609345QA (en) | 2012-02-07 | 2017-01-27 | Global Bio Therapeutics Inc | Compartmentalized method of nucleic acid delivery and compositions and uses thereof |
| WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
| DK2830595T3 (da) | 2012-03-29 | 2019-12-02 | Translate Bio Inc | Ioniserbare kationiske lipider |
| AU2013243952A1 (en) | 2012-04-02 | 2014-10-30 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| BR112014030677A2 (pt) | 2012-06-08 | 2022-07-19 | Shire Human Genetic Therapies | distribuição pulmonar de mrna para células-alvo não-pulmonares |
| US9512456B2 (en) | 2012-08-14 | 2016-12-06 | Modernatx, Inc. | Enzymes and polymerases for the synthesis of RNA |
| WO2014093924A1 (en) | 2012-12-13 | 2014-06-19 | Moderna Therapeutics, Inc. | Modified nucleic acid molecules and uses thereof |
| EP3628335B1 (en) | 2012-12-07 | 2023-11-08 | Translate Bio, Inc. | Lipidic nanoparticles for mrna delivery in the lungs |
| AU2013374345A1 (en) * | 2013-01-17 | 2015-08-06 | Moderna Therapeutics, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
| HK1220122A1 (zh) | 2013-03-09 | 2017-04-28 | Modernatx, Inc. | Mrna的异源未转录区域 |
| EP2970351B1 (en) | 2013-03-14 | 2017-09-13 | Translate Bio, Inc. | Ribonucleic acids with 4'-thio-modified nucleotides and related methods |
| JP6605446B2 (ja) * | 2013-03-15 | 2019-11-13 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | 形質移入用の脂質ナノ粒子および関連方法 |
| HUE071526T2 (hu) | 2013-03-15 | 2025-09-28 | Translate Bio Inc | Nukleinsavak bejuttatásának szinergista fokozása kevert kiszerelésekkel |
| US10023626B2 (en) * | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| TWI642782B (zh) * | 2013-10-23 | 2018-12-01 | 健臻公司 | 重組醣蛋白及其用途 |
| WO2015130584A2 (en) | 2014-02-25 | 2015-09-03 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
| SG10201912038TA (en) * | 2014-04-23 | 2020-02-27 | Modernatx Inc | Nucleic acid vaccines |
| IL298516B2 (en) | 2014-06-25 | 2025-03-01 | Acuitas Therapeutics Inc | Novel lipids and lipid nanoparticle compositions for nucleic acid delivery |
| WO2016118724A1 (en) * | 2015-01-21 | 2016-07-28 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| AU2016271519B2 (en) | 2015-06-05 | 2021-09-02 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for transient gene therapy with enhanced stability |
| CA2998810A1 (en) | 2015-09-17 | 2017-03-23 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| US11377656B2 (en) | 2016-03-10 | 2022-07-05 | Novartis Ag | Chemically modified messenger RNA's |
| WO2017191274A2 (en) | 2016-05-04 | 2017-11-09 | Curevac Ag | Rna encoding a therapeutic protein |
| EP3896164A1 (en) | 2016-05-18 | 2021-10-20 | ModernaTX, Inc. | Polynucleotides encoding alpha-galactosidase a for the treatment of fabry disease |
| CA3041350A1 (en) | 2016-11-10 | 2018-05-17 | Translate Bio, Inc. | Subcutaneous delivery of messenger rna |
-
2017
- 2017-05-18 EP EP21153545.5A patent/EP3896164A1/en not_active Withdrawn
- 2017-05-18 CA CA3024507A patent/CA3024507A1/en active Pending
- 2017-05-18 WO PCT/US2017/033398 patent/WO2017201328A1/en not_active Ceased
- 2017-05-18 JP JP2018560595A patent/JP7114485B2/ja active Active
- 2017-05-18 AU AU2017266932A patent/AU2017266932B2/en not_active Ceased
- 2017-05-18 EP EP17728702.6A patent/EP3458590B9/en active Active
-
2018
- 2018-08-23 US US16/110,833 patent/US10494636B2/en active Active
- 2018-08-23 US US16/110,788 patent/US20190000932A1/en not_active Abandoned
- 2018-08-23 US US16/110,309 patent/US10519455B2/en active Active
-
2019
- 2019-09-13 US US16/570,351 patent/US11649461B2/en active Active
-
2022
- 2022-07-27 JP JP2022119527A patent/JP2022136230A/ja active Pending
-
2023
- 2023-04-06 US US18/296,596 patent/US20230323371A1/en not_active Abandoned